OmniScience Joins NVIDIA Inception Program to Accelerate AI Innovation in Clinical Trials
Vivo’s expansion gains momentum through acceptance to NVIDIA Inception’s innovation ecosystem.
Houston, TX – May, 9, 2025 – OmniScience, the creator of Vivo—the first agentic AI clinical trial control tower—announces its acceptance into the NVIDIA Inception program. This prestigious global accelerator supports startups driving innovation in AI, deep learning, and data science.
OmniScience joins a curated network of cutting-edge companies and venture capital partners focused on advancing breakthrough technologies. Through NVIDIA Inception, the company will gain access to technical resources, go-to-market support, and a powerful ecosystem of collaborators across AI and healthcare.
“As we continue to scale Vivo and bring the power of agentic AI to clinical trials, being part of NVIDIA Inception is an exciting milestone,” said Colin Hendricks, CTO of OmniScience. “Access to NVIDIA’s deep expertise and expansive innovation network will help us accelerate the development of our platform and deliver greater value to sponsors, patients, and partners.”
Vivo is transforming the clinical development landscape by unifying fragmented data, providing real-time insights, and improving decision-making for clinical trials. Vivo empowers trial teams to reduce timelines, cut costs, and improve probability of success.
Acceptance into NVIDIA Inception reinforces OmniScience’s commitment to delivering transformative, high-impact AI technologies to the life sciences industry.
Connect with us
Our mission is to transform clinical trial operations to deliver life-changing medicines to patients faster. We built Vivo, the first agentic AI-powered control tower for clinical trials.
Vivo unifies fragmented clinical, safety, and operational data, and delivers real-time, explainable insights, putting teams ahead of the trial, not behind it. To learn more about Vivo, contact us at hello@omniscience.bio or connect with us on LinkedIn.
